We are live on ! Find out more
JGC

J. Goldman & Co Portfolio holdings

AUM $3.44B
1-Year Est. Return 33.8%
This Fund
S&P 500
This Quarter Est. Return
+10.74%
1 Year Est. Return
+33.8%
3 Year Est. Return
+89.45%
5 Year Est. Return
+82.14%
10 Year Est. Return
+407.39%
AUM
$1.39B
AUM Growth
+$62.3M
Cap. Flow
-$30.3M
Cap. Flow %
-2.17%
Top 10 Hldgs %
32.32%
Holding
406
New
134
Increased
46
Reduced
56
Closed
155

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$229M
2
PYPL icon
PayPal
PYPL
+$15.3M
3
FDX icon
FedEx
FDX
+$12.7M
4
JWN
Nordstrom
JWN
+$12.1M
5
MU icon
Micron Technology
MU
+$12M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 17.79%
2 Industrials 8.58%
3 Healthcare 7.87%
4 Technology 6.57%
5 Consumer Staples 3.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRTX
376
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
-4,446
Closed -$346K
WWE
377
DELISTED
World Wrestling Entertainment
WWE
-98,356
Closed -$7M
QUOT
378
PUT
DELISTED
Quotient Technology Inc
QUOT
-30,000
Closed -$235K
PING
379
DELISTED
Ping Identity Holding Corp.
PING
-111,350
Closed -$1.92M
EPZM
380
DELISTED
Epizyme, Inc
EPZM
-370,454
Closed -$3.82M
CNR
381
CALL
DELISTED
Cornerstone Building Brands, Inc.
CNR
-234,900
Closed -$1.42M
CONE
382
DELISTED
CyrusOne Inc Common Stock
CONE
-7,162
Closed -$567K
PAE
383
CALL
DELISTED
PAE Incorporated Class A Common Stock
PAE
-166,666
Closed -$209K
KSU
384
DELISTED
Kansas City Southern
KSU
-30,236
Closed -$4.02M
KDMN
385
DELISTED
Kadmon Holdings, Inc.
KDMN
-277,934
Closed -$700K
PGNX
386
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
-211,100
Closed -$1.07M
PGNX
387
DELISTED
Progenics Pharmaceuticals Inc
PGNX
-499,698
Closed -$2.53M
RTN
388
CALL
DELISTED
Raytheon Company
RTN
-20,000
Closed -$3.92M
RTN
389
DELISTED
Raytheon Company
RTN
-52,019
Closed -$10.2M
CRCM
390
DELISTED
CARE.COM, INC.
CRCM
-312,028
Closed -$3.26M
CBPX
391
CALL
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
-130,500
Closed -$3.56M
CBPX
392
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
-167,608
Closed -$4.57M
ARQL
393
DELISTED
Arqule Inc
ARQL
-425,621
Closed -$3.05M
ARQL
394
PUT
DELISTED
Arqule Inc
ARQL
-125,000
Closed -$896K
PSDO
395
DELISTED
Presidio, Inc. Common Stock
PSDO
-185,883
Closed -$3.14M
NFC.WS
396
CALL
DELISTED
New Frontier Corporation Warrants, each whole warrant exercisable for one Class A ordinary share at
NFC.WS
-89,800
Closed -$92K
RWGE
397
CALL
DELISTED
Regalwood Global Energy Ltd. Class A Ordinary Shares
RWGE
-129,900
Closed -$75K
RWGE
398
DELISTED
Regalwood Global Energy Ltd. Class A Ordinary Shares
RWGE
-500,000
Closed -$5.16M
NVTR
399
DELISTED
Nuvectra Corporation Common Stock
NVTR
-1,056,163
Closed -$1.44M
IPOA.WS
400
CALL
DELISTED
Social Capital Hedosophia Holdings Corp. Warrants, each whole warrant exercisable for one Class A Or
IPOA.WS
-100,778
Closed -$250K

Similar funds

J. Goldman & Co's Q4 2019 Portfolio in Review

As of Q4 2019, J. Goldman & Co held 406 positions worth $1.39B, up 4.7% from $1.33B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

J. Goldman & Co's Q4 2019 filing shows 134 new, 46 increased, 56 reduced and 155 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 741,000 shares worth $240M. The largest sale was Virgin Galactic, an estimated $37.5M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 17% a quarter earlier, followed by Industrials and Healthcare.

  • J. Goldman & Co's largest Q4 2019 buy was iShares Core S&P 500 ETF: 741,000 shares worth $240M.
  • J. Goldman & Co added most to FedEx in Q4 2019, an estimated $12.7M increase.
  • J. Goldman & Co's biggest Q4 2019 reduction was Jack in the Box, cutting an estimated $10.6M.
  • J. Goldman & Co fully exited Virgin Galactic in Q4 2019, selling an estimated $37.5M.
  • J. Goldman & Co's ten largest holdings make up 32% of its $1.39B portfolio in Q4 2019.
  • J. Goldman & Co opened 134 new positions and closed 155 in Q4 2019.
  • J. Goldman & Co's portfolio value rose 4.7% quarter-over-quarter to $1.39B.

Based on J. Goldman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.